Recent trends in the characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large U.S. claims database

International Journal of Clinical Practice

Volumn 67, Issue 5, 2013, Pages 449-454

  Brodovicz, K G ^a   Kou, T D ^a,b   Alexander, C M ^a   O'Neill, E A ^a   Senderak, M ^a   Engel, S S ^a   Girman, C J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLITAZONE DERIVATIVE; METFORMIN; ORAL ANTIDIABETIC AGENT; SITAGLIPTIN; SULFONYLUREA;

ADULT; AGE; ARTICLE; BILLING AND CLAIMS; BLINDNESS; COMBINATION CHEMOTHERAPY; COMORBIDITY; DATA BASE; FEMALE; GENDER; HEALTH INSURANCE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; RETINA MACULA EDEMA; RETINOPATHY; RISK ASSESSMENT; UNITED STATES;

ADMINISTRATION, ORAL; ADULT; AGE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PYRAZINES; TRIAZOLES; UNITED STATES;

EID: 84876477400     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12090     Document Type: Article

References (12)

1. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med 1991; 10: 577-81.
2. Brookhart MA, Sturmer T, Glynn RJ, Rassen J, Schneeweiss S. Confounding control in healthcare database research: challenges and potential approaches. Med Care 2010; 48: S114-20.
3. Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA. Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin Pharmacol Ther 2011; 90: 777-90.
4. Strom BL. Methodologic challenges to studying patient safety and comparative effectiveness. Med Care 2007; 45: S13-5.
5. Lobo FS, Wagner S, Gross CR, Schommer JC. Addressing the issue of channeling bias in observational studies with propensity scores analysis. Res Social Adm Pharm 2006; 2: 143-51. (Pubitemid 44144470)
6. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94: 311-21.
7. Roglic G, Unwin N. Mortality attributable to diabetes: estimates for the year 2010. Diabetes Res Clin Pract 2010; 87: 15-9.
8. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34. (Pubitemid 28350165)
9. Herman GA, Stein PP, Thornberry NA, Wagner JA. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther 2007; 81: 761-7. (Pubitemid 46625120)
10. Cai B, Katz L, Alexander CM, Williams-Herman D, Girman CJ. Characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large US claims database. Int J Clin Pract 2010; 64: 1601-8.
11. Zhang Q, Rajagopalan S, Mavros P et al. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycaemic agents: analysis of a US electronic medical record database. Curr Med Res Opin 2010; 26: 1697-703.
12. Chokrungvaranon N, Deer J, Reaven PD. Intensive glycemic control and cardiovascular disease: are there patients who may benefit? Postgrad Med 2011; 123: 114-23.